Point72 Hong Kong Ltd grew its stake in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 136.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,130 shares of the life sciences company’s stock after acquiring an additional 2,380 shares during the quarter. Point72 Hong Kong Ltd’s holdings in Integra Lifesciences were worth $241,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. First National Bank of Omaha grew its holdings in shares of Integra Lifesciences by 8.8% during the fourth quarter. First National Bank of Omaha now owns 45,430 shares of the life sciences company’s stock worth $2,648,000 after buying an additional 3,675 shares in the last quarter. Oxford Asset Management LLP increased its stake in Integra Lifesciences by 36.9% during the fourth quarter. Oxford Asset Management LLP now owns 18,829 shares of the life sciences company’s stock worth $1,097,000 after acquiring an additional 5,079 shares during the last quarter. Advisor Group Inc. increased its stake in Integra Lifesciences by 0.7% during the fourth quarter. Advisor Group Inc. now owns 33,610 shares of the life sciences company’s stock worth $1,960,000 after acquiring an additional 243 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Integra Lifesciences by 15.4% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 82,692 shares of the life sciences company’s stock worth $4,967,000 after purchasing an additional 11,028 shares during the period. Finally, Man Group plc raised its holdings in shares of Integra Lifesciences by 974.7% in the 3rd quarter. Man Group plc now owns 43,247 shares of the life sciences company’s stock worth $2,597,000 after purchasing an additional 39,223 shares during the period. 83.84% of the stock is currently owned by institutional investors and hedge funds.
IART has been the subject of a number of recent research reports. Piper Jaffray Companies lowered Integra Lifesciences from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $59.00 to $58.00 in a research note on Tuesday, January 7th. Piper Sandler lowered Integra Lifesciences from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $59.00 to $58.00 in a research report on Tuesday, January 7th. Credit Suisse Group decreased their price target on Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating for the company in a report on Friday, March 6th. ValuEngine raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, BidaskClub lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. Integra Lifesciences presently has an average rating of “Hold” and a consensus price target of $63.91.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 19th. The life sciences company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Integra Lifesciences had a return on equity of 16.90% and a net margin of 3.31%. The firm had revenue of $395.13 million during the quarter, compared to analyst estimates of $397.51 million. During the same quarter last year, the firm earned $0.65 EPS. Integra Lifesciences’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts predict that Integra Lifesciences Holdings Corp will post 3.02 earnings per share for the current fiscal year.
In other news, CEO Peter J. Arduini sold 32,316 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $55.68, for a total transaction of $1,799,354.88. Following the completion of the transaction, the chief executive officer now directly owns 274,891 shares in the company, valued at approximately $15,305,930.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.50% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Read More: Why are gap-down stocks important?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.